The Effect of Hydrogen-Rich Water on Dysmenorrhea and Menstrual Symptom Severity
ConditionDysmenorrhea Primary
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorMenekşe Nazlı AKER
About this trial
The study will include hydrogen-rich water and control groups. Young women with severe primary dysmenorrhea will be recruited from Ankara University. Eligible women will be informed about the study, and written informed consent will be obtained. Participants will be assigned to the study groups using block randomization.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Having regular menstrual cycles occurring every 21-35 days, with bleeding lasting 2-7 days,
Having severe dysmenorrhea according to the WaLIDD score (8-12 points),
Having primary dysmenorrhea,
Being older than 18 years.
Disqualifiers
Regular use of analgesics and anti-inflammatory medications,
Having any gynecological condition (e.g., abnormal uterine bleeding, uterine fibroids, ovarian cysts, or endometriosis),
Use of hormonal contraceptives and/or an intrauterine device.
Trial design
Design model
Parallel
Treatments tested in this trial
Hydrogen-rich water consumption
Other interventionParticipants will begin consuming hydrogen-rich water after menstruation ends in the baseline cycle and continue daily for three months. They will be asked to drink 1,500-2,000 mL (1.5-2.0 L) per day. Adherence will be monitored using a daily water intake log.
Drinking water consumption
Other interventionParticipants will begin consuming water after menstruation ends in the baseline cycle and continue daily for three months. They will be asked to drink 1,500-2,000 mL (1.5-2.0 L) per day. Adherence will be monitored using a daily water intake log.
Treatment groups
48 Participants
are divided into 2 treatment groupsGroup A: Intervention GroupExperimental treatment 1 intervention
Group B: Control GroupPlacebo comparator 1 intervention
Trial outcomes
Primary outcomes
1
WaLIDD Score
The WaLIDD Score was developed by Teherán et al. The scale, which underwent a Turkish validity and reliability study by Fidancı et al. in 2025, is a four-item assessment tool. Each item is scored between 0 and 3 points, yielding a total score range of 0-12. The scale evaluates four dimensions: work affected (the impact of pain on daily functioning), localization of pain (the anatomical distribution of pain), intensity of pain (a subjective assessment based on the Wong-Baker Faces Pain Scale), and duration of pain (the number of painful days during menstruation). A total score of "0" indicates no dysmenorrhea, scores of "1-4" indicate mild dysmenorrhea, scores of "5-7" indicate moderate dysmenorrhea, and scores of "8-12" indicate severe dysmenorrhea.
Time frame
Baseline (days 5-7 of the first menstrual cycle) and follow-up (days 5-7 of the third menstrual cycle)Secondary outcomes
1
Menstrual Symptom Questionnaire
The Menstrual Symptom Questionnaire was developed by Chesney and Tasto. The scale, which underwent a Turkish validity and reliability study by Güvenç in 2014, consists of twenty-two items rated on a five-point Likert-type format. Participants rate their menstrual symptoms on a scale from 1 to 5, where 1 indicates "never" and 5 indicates "always." The total score of the Menstrual Symptom Questionnaire is obtained as the mean of the sum of all items. In the original version of the scale, there are three subdimensions: negative affect/somatic complaints, menstrual pain, and abdominal pain.
Time frame
Baseline (days 5-7 of the first menstrual cycle) and follow-up (days 5-7 of the third menstrual cycle)Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Menekşe Nazlı AKER
Lead sponsor
Ankara University
Sponsor institution
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: